IMTX
NASDAQ · Biotechnology
Immatics Nv
$9.78
+0.58 (+6.30%)
Financial Highlights (FY 2026)
Revenue
202.41M
Net Income
19.77M
Gross Margin
—
Profit Margin
9.8%
Rev Growth
+64.8%
D/E Ratio
0.03
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 33.2% | 33.2% |
| Operating Margin | -24.8% | -22.3% | -15.4% | -12.4% |
| Profit Margin | 9.8% | 9.3% | -10.9% | -15.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 202.41M | 122.80M | 330.72M | 310.79M |
| Gross Profit | — | — | 109.78M | 103.16M |
| Operating Income | -50,156,218 | -27,386,153 | -50,879,176 | -38,649,824 |
| Net Income | 19.77M | 10.79M | -35,950,365 | -46,474,411 |
| Gross Margin | — | — | 33.2% | 33.2% |
| Operating Margin | -24.8% | -22.3% | -15.4% | -12.4% |
| Profit Margin | 9.8% | 9.3% | -10.9% | -15.0% |
| Rev Growth | +64.8% | +64.8% | -2.7% | -3.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 18.66M | 18.66M | 416.60M | 451.59M |
| Total Equity | 661.71M | 661.71M | 804.78M | 720.44M |
| D/E Ratio | 0.03 | 0.03 | 0.52 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -38,714,040 | -22,312,890 | -62,958,224 | -63,441,351 |
| Free Cash Flow | — | — | -53,039,983 | -41,589,145 |